Meeting
2015 ASCO Annual Meeting
Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience.
Authors
Han Hsi Wong
Cancer Research UK Centre for Drug Development, London, United Kingdom
Han Hsi Wong , Claire Barton , Gary Acton , Robert McLeod , Rachel Darby-Dowman , Janette McQuillan , Helen Turner , Susan Wan , Zoe Backholer , Jane Peters , Sarah E. R. Halford
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Cytotoxic and Other Novel Agents
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2534)
DOI
10.1200/jco.2015.33.15_suppl.2534
Abstract #
2534
Poster Bd #
250
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
A phase I clinical trial of QBI-139, a human ribonuclease variant, in solid tumors.
First Author: L. E. Strong
Poster
2023 ASCO Annual Meeting
Utilizing Drug Combo to improve the design of phase 1 trials for anticancer drugs.
First Author: Lei Wang
Poster
2022 ASCO Annual Meeting
Phase I study of epacadostat in combination with sirolimus in advanced malignancy.
First Author: Chao Hui Huang
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.
First Author: Wen Wee Ma